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In January 2020, the etiologic agent responsible for a cluster of severe pneumonia cases in Wuhan, China, 
was identified as a novel beta-coronavirus (2019-nCoV), distinct than SARS-CoV and MERS-CoV (1) (2) (3). 
The complete genomic sequence of this new agent is available and different detection protocols have been 
developed, although they have not been fully validated yet. However, in light of the possible introduction of 
a suspected case related to 2019-nCoV in the Region of the Americas, the Pan American Health 
Organization / World Health Organization (PAHO / WHO) recommends that Member States ensure its 
timely identification either by the shipment of the samples to national or reference laboratories, or the 
implementation of the molecular detection protocol for 2019-nCoV, depending on the laboratory's 
capacity. 
 
To date, the pathogenic potential and transmission dynamics of 2019-nCoV is not fully understood. For this 
reason and in the light of the knowledge of other similar viruses (e.g., MERS-CoV, SARS-CoV), it is necessary 
to maintain and strengthen biosafety measures including personal protection procedures, to work with 
samples from suspected cases of respiratory pathogen infection. 
 
General recommendations for working with potentially infectious material2 
 
Laboratory personnel should wear appropriate personal protective equipment (PPE) that includes 
disposable gloves, surgical mask, anti-fluid gown, and eye protection when handling potentially infectious 
samples. 
 
When collecting a respiratory sample from a suspected patient in the Intensive Care Unit, the use of N95 
masks is highly recommended. 
 
Any procedure with the potential to generate fine particle aerosols (for example, sample preparation with 
open tubes or vortexing) must be performed in a certified Class II biosafety cabinet (BSC). Appropriate 
physical restraint devices (e.g., centrifuge safety buckets and sealed rotors) should be used for 
centrifugation. Ideally, centrifuge rotors should be loaded and unloaded in a BSC. Any procedure within the 
laboratory which generates aerosols and is performed outside a BSC (or the cleaning up highly suspicious 
samples spilling, for example) must be performed using N95 mask. 
 
After sample processing, decontaminate work surfaces and equipment with the appropriate disinfectants. 
To this end, use any registered hospital disinfectant. The manufacturer's recommendations for use/dilution 
(i.e., concentration), contact time and care in handling should be followed. 
 
All disposable material must be autoclaved before final disposal. 
 
1 The recommendations made in this document can be subject to later modifications in accordance to the advances in 
the knowledge of the disease and the etiologic agent. 
 
2 These recommendations are based on the CDC’s Interim Laboratory Biosafety Guidelines for Handling and Processing 
Specimens Associated with 2019 Novel Coronavirus (2019-nCoV): 
https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html 
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Specific recommendations for the handling of samples that may contain 2019-
nCoV 
 
To avoid amplification and concentration of viral particles, it is NOT recommended to attempt viral 
isolation in cell culture. 
 
The following procedures may be performed in BSL-2 facilities using standard work practices: 
 
• Pathologic examination and processing of formalin-fixed or otherwise inactivated tissues 
• Plate setup for molecular analysis of already extracted viral nucleic acids 
• Electron microscopic studies with glutaraldehyde-fixed grids 
• Routine (visual) examination of bacterial and mycotic cultures 
• Routine staining and microscopic analysis of fixed smears 
• Final packaging of specimens for transport to diagnostic laboratories for additional testing. Samples 
should already be in a sealed, decontaminated primary container. 
• Inactivated specimens (specimens in nucleic acid extraction buffer) 
 
The following procedures must be performed in a Class II BSC: 
 
• Aliquoting and/or diluting samples 
• Inoculating bacterial or mycological culture media 
• Performing diagnostic tests that do not involve propagation of viral agents in vitro or in vivo (e.g., 
preparing slides for immunofluorescence) 
• Nucleic acid extraction procedures involving potentially infected specimens 
• Preparation and chemical- or heat-fixing of smears for microscopic analysis 
 
International regulations for the safe transport of infectious substances 
 
The safe packing, shipping and transport of samples that may contain 2019-nCoV must follow the current 
edition of the International Air Transport Association (IATA) Dangerous Goods Regulations (4). 
Planning the logistics of the shipment 
• Identify the name and contact details (phone and / or e-mail) of the technical officer for the event 
at the national reference laboratory, National Influenza Center (NIC), or international reference 
laboratory, who should be attentive until the shipment is received 
• Notify the laboratory (NIC or reference laboratory) of the shipment of the sample 
• Contact the transporting company to verify schedules and itineraries 
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Rigid, leak-proof secondary container 
Rigid shipping box (tertiary – outer-
container). For air shipping, a P650 
(Category B) should be used. 
Preparing the material for packaging 
The transport of samples that may contain 2019-nCoV must use triple packaging and comply with 
international standards related to air transport of infectious substances: “Biological Substance, Category B”. 
 
 
 
 
 
 
 
 
  
 
Packing the sample    
 
 
 
 
 
 
 
 
 
 
 
 
Absorbent material enough to absorb the 
entire liquid content 
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Packing of refrigerated samples (recommended) 
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Marks and labels 
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Mandatory triple packaging model for air shipments that can be used to comply 
with the P650 instruction for Biological Substances, Category B. 
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Documentation that must accompany the shipment (Biological substances, Cat. B) 
For the transport of samples, it is important that the shipper prepares the required documentation 
according to the applicable regulations, in order to inform those who are going to transport the package 
(i.e., the carrier, the courier or the logistics specialist) about the way in which it was prepared and about its 
content. 
All information provided in transport documents must be easy to read and written so that it cannot be 
altered (for example, with permanent ink that cannot be easily removed). 
• Air waybill 
An air waybill must accompany all shipments made by air (Cat. A, Cat. B and exempt material). 
The shipper or transport company will be responsible for completing the information in the air waybill. 
 
Model of air waybill for shipping of Biological Substances, Cat. B with dry ice 
(recommended) 
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• Import permit 
In some instances, the laboratory that receives the sample requires a permit to import the biological 
material. A valid import permit must be requested in advance from the institution and should indicate the 
details of the person responsible for receiving the package. 
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• Sample Submission Form 
To facilitate the identification, analysis and monitoring of cases, it is important to provide the reference 
laboratory with detailed information regarding each sample. There are different formats that can be used 
to summarize epidemiological and clinical data. 
 
 
 
 
 
  
 
 
nCoV - biosafety and shipping 10 
 
 
References 
 
1. Hui, DSC and Zumla, A. Severe Acute Respiratory Syndrome - Historical, Epidemiologic; and Clinical 
Features. [book auth.] HW Boucher, A Zumla and DSC Hui. Emerging and Re-emerging Infectious Diseases - 
Clinics Revew Articles . Philadelphia : Elsevier, 2019, pp. 869-889. 
2. Drosten , C, et al. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol 
Med. 2003, Vol. 9, pp. 325-7. 
3. GISAID. Newly discovered betacoronavirus, Wuhan 2019-2020. GISAID EpiFlu - Global Initiative on 
Sharing All Influenza Data. [Online] January 2020. https://platform.gisaid.org/epi3/frontend#414223. 
4. World Health Organization. Guidance on regulations for the transport of infectious substances 2019–
2020. [Online] 2019. [Cited: January 28, 2020.] https://www.who.int/ihr/publications/WHO-WHE-CPI-
2019.20/en/. 
 
